Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study
Chinese authority approved nirsevimab to prevent respiratory syncytial virus (RSV) in January 2024. We aimed to assess the cost-effectiveness of nirsevimab immunization among infants in Shanghai. A decision-tree Markov model was developed to compare two strategies – year-round and seasonal immunizat...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2506288 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!